SOCRATES-PRESERVED

• Research type

  Research Study

• Full title

  A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dose regimens of the oral sGC stimulator BAY 1021189 over 12 weeks in patients with worsening heart failure and preserved ejection fraction.

• IRAS ID

  152688

• Contact name

  Diana Gorog

• Contact email

  d.gorog@nhs.net

• Eudract number

  2013-002288-25

• Research summary

  Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be give in addition to standard therapy for heart failure with preserved ejection fraction (HFpEF).

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  14/LO/0676

• Date of REC Opinion

  4 Jun 2014

• REC opinion

  Further Information Favourable Opinion